Difference between revisions of "Sonidegib (Odomzo)"
Warner-admin (talk | contribs) |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Hedgehog pathway inhibitor. Sonidegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog signal transduction pathway that is clinically relevant in diseases such as basal cell cancer.<ref name="insert">[ | + | Class/mechanism: Hedgehog pathway inhibitor. Sonidegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog signal transduction pathway that is clinically relevant in diseases such as basal cell cancer.<ref name="insert">[https://www.odomzo.com/themes/custom/odomzo/global/pdfs/pi.pdf Sonidegib (Odomzo) package insert]</ref><ref>[[Media:Sonidegib.pdf | Sonidegib (Odomzo) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 13: | Line 13: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *7/24/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455865.htm Initial FDA approval] | + | *7/24/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455865.htm Initial FDA approval] for the treatment of patients with locally advanced [[Cutaneous basal cell carcinoma|basal cell carcinoma (BCC)]] that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ''(Based on BOLT)'' |
==Also known as== | ==Also known as== | ||
Revision as of 19:48, 25 May 2021
General information
Class/mechanism: Hedgehog pathway inhibitor. Sonidegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog signal transduction pathway that is clinically relevant in diseases such as basal cell cancer.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 7/24/2015: Initial FDA approval for the treatment of patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. (Based on BOLT)
Also known as
- Code name: LDE225
- Generic name: erismodegib
- Brand name: Odomzo